Psychiatry

New research finds association common sleep disorder present in 14% of suicidal patients with major depressive disorder studied.

Burnout non-profit founder Janae Sharp will lead a chat on what's working in addressing physician burnout—and what's still lacking.

Intec Pharma announces clinical trial failure after finding new drug did not have a market difference treating PD from existing medications.

New research shows keeping a diary while in the ICU does not prevent PTSD symptoms from occurring.

Several new generics available to treat neuropathic pain linked to diabetic peripheral neuropathy, fibromyalgia partial onset seizures, and other conditions.

Moving forward following failed studies in Alzheimer disease and improving how the condition is managed in the future.

An in-depth review of mechanisms linked to the pathogenesis of Alzheimer disease, including amyloid and tau.

Ronald C. Petersen, MD, PhD, discusses the relationship between genetics and the risk for developing Alzheimer disease, as well as highlights efforts of the Generation Program.

The meta-analysis was comprised of 402 individual studies in which the primary therapy was 1 of 32 antipsychotics.

The majority of physicians who exhibit burnout symptoms receive more than the average number of system-generated in-basket messages.

How the thought of AD has changed to interpret the disease's pathology, and why that has benefitted clinicians.

AD symptoms can take years to manifest, making clinical trials difficult. Investigators are fixed on finding disease biomarkers.

Investigators examined more than 3500 adolescents and found associations between computer and social media use, but not video game and television use.

Leading a healthy lifestyle can decrease a person's risk of dementia, even if a patient already has a high genetic risk, according to a new study.

A clinical trial of 147 individuals found that a 15-week treatment program using cognitive behavioral therapy may be a promising treatment for internet and video game addictions.

A recent study from investigators at the Penn State College of Medicine found that atypical eating behaviors were present in 70.4% of children with autism.

What new drug classes are catching the most traction among clinicians?

A recent study found that young people with life-limiting conditions had higher prevalence rates of both anxiety and depression.

For healthcare executives at all levels, addressing burnout is an urgent priority, one directly impacting their overall mission of improving quality of care and patient experience as well as retaining physicians and advanced practitioners.

A recent study of more than 50,000 found that antidepressant use could reduce a third of deaths among diabetic patients with depression.

The NMDA receptor, in combination with rehabilitation, may serve as a powerful agent for reducing relapse rates.

The lead investigator of a new meta-analysis shared the critical need for further studies on psychotherapeutic versus pharmacological treatments for PTSD.

A new meta-analysis showed that while psychotherapeutic treatments are generally preferred, there’s a dearth of data with which to defend that decision.

A recent study from ADA 2019 found that rates of depression, mental illness, and antidepressant use among diabetes patients have increased significantly from 2010 to 2016.

Contrary to earlier research, investigators found that medical cannabis laws do not reduce deaths caused by opioid overdoses.

Patients who self-referred themselves to a hospital for suicidal and/or self-harming actions did not improve more than patients who received standard treatment apart from hospitalization.

Children exposed in utero to valproate were most affected, but exposure to 3 other monotherapies were also associated with behavioral issues.

A new study shows that loss of phosphodiesterase, not just dopamine, indicates a worsening of motor symptoms in patients with Parkinson disease.

The nasal spray was shown to reduce relapse in patients who achieved remission or stability after 16 weeks of treatment plus antidepressant.

The approval is based on the findings of a 106-adult patient trial which assessed mean weekly headache episodes.